Efficacy of the combination of furosemide plus chlorthalidone versus a high dose furosemide on overhydration status in advanced chronic kidney disease: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240317001

Enrollment

Registered

2024-03-17

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subclinical fluid overload in CKD stage 3-4 chronic kidney disease, fluid overload, furosemide, chlorthalidone

Interventions

25 mg of chlorthalidone + 40 mg of furosemide one time per day duration: 1 week then evaluate for safety and efficacy complete follow up at 4 weeks,40 mg of furosemide x 2 tablets duration: 1 week the

Active Comparator Drug,Active Comparator Drug

25 mg of chlorthalidone + 40 mg of furosemide,40 mg of furosemide x 2 tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. CKD stage 3-4 2. volume overload by BCM > 1.1 liter

Exclusion criteria

Exclusion criteria: 1. recent heart failure with in 1 month 2. recent hospitalization within 1 month 3. pregnancy 4. recent kidney injury with in 1 month 5. cirrhosis child B-C 6. life expectancy < 6 months 7. allergy to sulfa

Design outcomes

Primary

Measure	Time frame
change in overhydration status at first week body composition monitoring (overhydration status in liter)	—

Secondary

Measure	Time frame
change in overhydration status fourth week body composition monitoring (overhydration status in liter),change in Na, K, HCO3, NTpBNP first and fourth week blood chemistry test,change in UACR first and fourth week urine analysis	—

Countries

Thailand

Contacts

Public ContactKOMCHAN UTAMAWATIN

PHRAMONGKUTKLAO HOSPITAL

milano_bcc156@hotmail.com027639300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026